ATE321069T1 - Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) - Google Patents

Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)

Info

Publication number
ATE321069T1
ATE321069T1 AT01943357T AT01943357T ATE321069T1 AT E321069 T1 ATE321069 T1 AT E321069T1 AT 01943357 T AT01943357 T AT 01943357T AT 01943357 T AT01943357 T AT 01943357T AT E321069 T1 ATE321069 T1 AT E321069T1
Authority
AT
Austria
Prior art keywords
pathological
growth factor
arteriogenesis
pigf
vascular
Prior art date
Application number
AT01943357T
Other languages
English (en)
Inventor
Peter Carmeliet
Desire Collen
Falco Sandro De
Ruvo Menotti
Original Assignee
Vlaams Interuniv Inst Biotech
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171493&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE321069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Interuniv Inst Biotech, D Collen Res Foundation Vzw filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE321069T1 publication Critical patent/ATE321069T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01943357T 2000-05-12 2001-05-10 Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) ATE321069T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00201714 2000-05-12

Publications (1)

Publication Number Publication Date
ATE321069T1 true ATE321069T1 (de) 2006-04-15

Family

ID=8171493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943357T ATE321069T1 (de) 2000-05-12 2001-05-10 Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)

Country Status (10)

Country Link
US (8) US7482004B2 (de)
EP (1) EP1297016B1 (de)
AT (1) ATE321069T1 (de)
AU (2) AU2001265953B2 (de)
CA (1) CA2407858C (de)
DE (1) DE60118186T2 (de)
DK (1) DK1297016T3 (de)
ES (1) ES2260234T3 (de)
PT (1) PT1297016E (de)
WO (1) WO2001085796A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265953B2 (en) * 2000-05-12 2005-09-29 D. Collen Research Foundation Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
GB2374870A (en) * 2001-01-26 2002-10-30 Thromb X Nv Use of genetically modified multicellular animals in the identification of drug target proteins
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP2228389B1 (de) * 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antikörper gegen vaskulären Endothelwachstumsfaktor 2
GB2384706A (en) * 2002-02-04 2003-08-06 Thromb X Nv Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
ITRM20020277A1 (it) * 2002-05-17 2003-11-17 Geymonat Spa Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
AU2003251729A1 (en) * 2002-06-28 2004-01-19 K.U.Leuven Research & Development Use of antibodies against flt-1 for the treatment of osteoporosis
WO2004046722A2 (de) * 2002-11-16 2004-06-03 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
WO2004078786A1 (en) * 2003-03-07 2004-09-16 Anges Mg Inc. Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
CN1890234A (zh) 2003-12-23 2007-01-03 辉瑞大药厂 新颖的喹啉衍生物
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US7598043B2 (en) * 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
JP5164829B2 (ja) 2005-03-24 2013-03-21 トロンボジェニクス・ナムローゼ・フエンノートシャップ 新規な抗ｐｌｇｆ抗体
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
WO2007003609A1 (en) * 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
CN100355882C (zh) * 2005-12-05 2007-12-19 中国人民解放军军事医学科学院放射与辐射医学研究所 杂交瘤细胞株及其产生的抗人vegfr－3的单克隆抗体
CA2669260C (en) * 2006-11-09 2019-01-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
AU2014200453B2 (en) * 2006-11-09 2015-06-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
JP5797403B2 (ja) * 2007-08-03 2015-10-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトモノクローナル抗体およびそれを産生する方法
CN101918839A (zh) 2008-01-07 2010-12-15 奥索临床诊断有限公司 sFlt-1:血管生成因子络合物的测定
US20110059445A1 (en) 2008-03-28 2011-03-10 Paul Rutgeerts Mucosal gene signatures
EP2352761B1 (de) 2008-10-02 2016-06-22 Vib Vzw Inhibierung von plgf zur behandlung von philadelphia chromosom positiver leukämie
GB0914318D0 (en) 2009-08-14 2009-09-30 Medical Res Council Method
DE102010013555A1 (de) 2010-03-31 2011-10-06 Christian Hamm Verwendung der Biomarker sFlt und PIGF in der Diagnose und Therapie der pulmonalen Hypertonie
WO2012151574A1 (en) 2011-05-05 2012-11-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
WO2017201166A1 (en) * 2016-05-17 2017-11-23 Duke University Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
CA3112175A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
CN112996528A (zh) * 2018-09-11 2021-06-18 安必圣有限责任公司 肽及其医学用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
JP3353209B2 (ja) * 1992-04-03 2002-12-03 ジェネンテク，インコーポレイテッド αｖβ３インテグリンに対する抗体
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
JP4532733B2 (ja) * 1998-03-17 2010-08-25 ジェネンテック， インコーポレイテッド Ｖｅｇｆおよびｂｍｐ１と相同なポリペプチド群
CA2332336A1 (en) 1998-05-26 1999-12-02 Erik Depla Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
WO2001057067A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
AU2001265953B2 (en) * 2000-05-12 2005-09-29 D. Collen Research Foundation Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
AU2003251729A1 (en) * 2002-06-28 2004-01-19 K.U.Leuven Research & Development Use of antibodies against flt-1 for the treatment of osteoporosis
JP5164829B2 (ja) * 2005-03-24 2013-03-21 トロンボジェニクス・ナムローゼ・フエンノートシャップ 新規な抗ｐｌｇｆ抗体
WO2007003609A1 (en) * 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications

Also Published As

Publication number Publication date
US20090074765A1 (en) 2009-03-19
EP1297016A2 (de) 2003-04-02
EP1297016B1 (de) 2006-03-22
DE60118186T2 (de) 2006-12-28
ES2260234T3 (es) 2006-11-01
WO2001085796A3 (en) 2002-04-04
PT1297016E (pt) 2006-07-31
AU2001265953B2 (en) 2005-09-29
CA2407858A1 (en) 2001-11-15
WO2001085796A2 (en) 2001-11-15
AU6595301A (en) 2001-11-20
US20090162354A1 (en) 2009-06-25
US20130177565A1 (en) 2013-07-11
US20130183310A1 (en) 2013-07-18
US20120263710A1 (en) 2012-10-18
US7482004B2 (en) 2009-01-27
DE60118186D1 (de) 2006-05-11
US20090238826A1 (en) 2009-09-24
CA2407858C (en) 2015-10-27
DK1297016T3 (da) 2006-07-10
US20030180286A1 (en) 2003-09-25
US20130177564A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
ATE321069T1 (de) Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
DE60315355D1 (de) Piperidinyl-thiazol-carbonsäure-derivate als angiogenesis inhibitoren
DE69931794D1 (de) Therapeutische zusammensetzungen zur behandlung von schleimhypersekretion
DE50109164D1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
MXPA03006806A (es) Metodo para usar variante del receptor del factor de crecimiento celular endotelial vascular para tratar psoriasis y para mejorar curacion de heridas.
ATE368457T1 (de) Tyrosinkinase inhibitoren
ATE399203T1 (de) Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung
DE60023926D1 (de) Tyrosin kinase inhibitoren
DE60018782D1 (de) Tyrosin kinase inhibitoren
DE60226154D1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
ATE421877T1 (de) Verwendung von totarol zur behandlung von pruritus
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
ATE446514T1 (de) VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
ATE345788T1 (de) Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
DE60307237D1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
MX2022016237A (es) Proteinas actrii para el tratamiento de la hipertension arterial pulmonar (hap).
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
IS7200A (is) Notkun á írbesartan til framleiðslu á lækningalyfjum sem notuð eru til að koma í veg fyrir eða meðhöndla lungnaháþrýsting
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1297016

Country of ref document: EP